Micafungin: pharmacology, experimental therapeutics and clinical applications

被引:26
作者
Groll, AH [1 ]
Stergiopoulou, T
Roilides, E
Walsh, TJ
机构
[1] Univ Munster, Med Ctr, Ctr Bone Marrow Transplantat, Univ Childrens Hosp, D-4400 Munster, Germany
[2] Univ Munster, Med Ctr, Infect Dis Res Program, Dept Pediat Hematol Oncol, D-4400 Munster, Germany
[3] NCI, Immunocompromised Host Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA
[4] Aristotle Univ Thessaloniki, Hippokration Hosp, Paediat Dept 3, GR-54642 Thessaloniki, Greece
关键词
1,3-beta-D-glucan synthesis; antifungal therapy; Aspergillus spp; Candida spp; echinocandin; FK-463; micafungin; pharmacokinetics; pharmacology;
D O I
10.1517/13543784.14.4.489
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Invasive fungal infections are important causes of morbidity and mortality in hospitalised patients. Current therapy with amphotericin B and antifungal triazoles has overlapping targets and is limited by toxicity and resistance. Echinocandins are a new class of antifungal drugs, which inhibit the synthesis of 1,3-beta-D-glucan. This homopolysaccharide is an important component of the cell wall of many pathogenic fungi, providing osmotic stability and functioning in cell growth and cell division. Micafungin, which is a member of the echinocandin class, exhibits in vitro fungicidal or fungistatic activity against a variety of fungal pathogens which include Candida and Aspergillus species but not Cryptococcus, Fusarium or Zygomyce.tes. Micafungin demonstrates linear pharmacokinetics, which are not altered by drugs metabolised through the P450 enzyme system. The preclinical and clinical data strongly support the development of micafungin for treatment of proven or suspected mucosal and invasive Candida infections in immunocompetent and immuno-compromised patients. This paper reviews the preclinical and clinical pharmacology of micafungin and its potential role for treatment of fungal invasive infections in patients.
引用
收藏
页码:489 / 509
页数:21
相关论文
共 69 条
[41]  
OSTROSKYZEICHNE.L, 2000, 40 INT C ANT AG CHEM, P197
[42]  
OSTROSKYZEICHNE.L, 2002, 42 INT C ANT AG CHEM, pM1816
[43]   Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits [J].
Petraitis, V ;
Petraitiene, R ;
Groll, AH ;
Roussillon, K ;
Hemmings, M ;
Lyman, CA ;
Sein, T ;
Bacher, J ;
Bekersky, I ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (06) :1857-1869
[44]   Combination therapy in treatment of experimental pulmonary aspergillosis: Synergistic interaction between an antifungal triazole and an echinocandin [J].
Petraitis, V ;
Petraitiene, R ;
Sarafandi, AA ;
Keleher, AM ;
Lyman, CA ;
Casler, HE ;
Sein, T ;
Groll, AH ;
Becher, J ;
Avila, NA ;
Walsh, TJ .
JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (12) :1834-1843
[45]  
PETRAITIS V, 1999, 39 INT C ANT AG CHEM, P2003
[46]  
PETRAITIS V, 2003, 13 M FOC FUNG INF, pP59
[47]  
Pettengell K, 1999, 39 INT C ANT AG CHEM, P1421
[48]  
PETTENGELL K, 2000, 40 INT C ANT AG CHEM, P1104
[49]  
Powles R, 2001, BLOOD, V98, p208A
[50]  
POWLES R, 2001, 41 INT C ANT AG CHEM, pJ676